CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 59 enrolled
Drug / intervention
ClearWay™ Rx catheterdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01673893
NCT01673893N/ACompleted

ClearWay Rx Readmission Registry

Cardiovascular Institute of the South Clinical Research Corporation·observational·Posted Aug 28, 2012·Updated Nov 29, 2018

In Brief

An observational study evaluating ClearWay™ Rx catheter for Acute Myocardial Infarction. Completed, enrolled 59 participants across 1 site.

Detailed Summary

The purpose of this registry is to determine if delivery of weight adjusted, in a large dose with either Abcixmab or Eptifibitide through the ClearWay™ RX, in patients admitted for primary coronary intervention lowers readmission rate. This is done in comparison to the historical control of the Medicare/Medicaid readmission database. The registry will record the use of the product during the index procedure, and determine whether or not the patient was readmitted within 30 days, related to the index procedure.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 28, 2012
Enrollment StartSep 1, 2011
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 13.8 years ago

Interventions

ClearWay™ Rx catheterdevice